Comparing AC Immune (ACIU) and Its Rivals

AC Immune (NASDAQ: ACIU) is one of 186 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its competitors? We will compare AC Immune to similar businesses based on the strength of its dividends, earnings, institutional ownership, analyst recommendations, risk, profitability and valuation.

Analyst Ratings

This is a summary of recent ratings and recommmendations for AC Immune and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AC Immune 0 0 1 0 3.00
AC Immune Competitors 572 2507 6736 133 2.65

AC Immune presently has a consensus target price of $18.00, suggesting a potential upside of 35.64%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 12.11%. Given AC Immune’s stronger consensus rating and higher probable upside, analysts plainly believe AC Immune is more favorable than its competitors.


This table compares AC Immune and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AC Immune N/A N/A N/A
AC Immune Competitors -4,594.03% -35.12% -43.24%

Valuation and Earnings

This table compares AC Immune and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
AC Immune $23.55 million -$7.20 million -19.81
AC Immune Competitors $217.40 million -$39.40 million -59.08

AC Immune’s competitors have higher revenue, but lower earnings than AC Immune. AC Immune is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

17.1% of AC Immune shares are held by institutional investors. Comparatively, 49.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 14.7% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


AC Immune beats its competitors on 8 of the 12 factors compared.

AC Immune Company Profile

AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn, among others.

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with's FREE daily email newsletter.

Leave a Reply